Skip to main content
. 2023 May 17;14:1148209. doi: 10.3389/fimmu.2023.1148209

Figure 5.

Figure 5

Effects of glucagon-like peptide-1 receptor agonist on non-alcoholic fatty liver disease. PPAR-α, Peroxisome proliferator-activated receptor; IHL, intrahepatic lipids; AMPK, AMP-activated protein kinase; CRP, C reactive protein; AGEs, Advanced glycation and end products; JNK, c-Jun NH2-terminal kinase; GLP-1RA, Glucagon-like peptide-1 receptor agonist; NAFLD, Non-alcoholic fatty liver disease (53). Modified figure from reference 53. Figure from Open access (World Journal of Gastroenterology) permissible to re-use under a CC-BY 4.0 license).